Julie Eggington, MS, PhD

Julie Eggington, MS, PhD has a wealth of experience in the field of genomic interpretation. Julie began their career in 2013 as Senior Director of Variant Sciences at Courtagen Life Sciences, Inc., where they worked with genetic mutations that cause a spectrum of disorders. In 2015, they moved to 23andMe as Director of Variant Classification Science, where they designed a high throughput variant classification pipeline for direct to consumer (DTC) next generation sequencing (NGS) high impact health panels. In 2016, they co-founded GeneInt, LLC, an expert consultation services company in the clinical science specialty of genetic testing.

In 2017, Eggington co-founded the Center for Genomic Interpretation (CGI), an independent 501(c)(3) non-profit organization dedicated to saving and improving lives by encouraging careful stewardship of clinical genetics, genomics, and precision medicine. Julie also became an Affiliate Faculty at Brigham Young University in 2018, mentoring students in the Life Sciences. In 2019, they became a Delphi Committee Member of the NIH funded Sulston Project, and in 2020 they became a CDC Next Generation Sequencing Best Practices Forum Nominated Member and a Standardizing Laboratory Practices in Pharmacogenomics Community Invited Member. Most recently, in 2021, Eggington became a Principal Consultant at Grandview Consulting LLC and a Kearns Community Advisory Committee Member for the Utah Department of Health.

Julie Eggington completed their Bachelor of Science in Honors Biochemistry, with a minor in Physics, at Brigham Young University in 1999. Julie then went on to pursue a Master of Science in Biochemistry at the University of Utah, which they completed in 2002. Finally, they obtained their Ph.D. in Biochemistry from the University of Wisconsin-Madison in 2006.